首页> 外文OA文献 >Advancing Basal Insulin Replacement in Type 2 Diabetes Inadequately Controlled With Insulin Glargine Plus Oral Agents: A Comparison of Adding Albiglutide, a Weekly GLP-1 Receptor Agonist, Versus Thrice-Daily Prandial Insulin Lispro.

【2h】

Advancing Basal Insulin Replacement in Type 2 Diabetes Inadequately Controlled With Insulin Glargine Plus Oral Agents: A Comparison of Adding Albiglutide, a Weekly GLP-1 Receptor Agonist, Versus Thrice-Daily Prandial Insulin Lispro.

机译：推进基础胰岛素替代2型糖尿病与胰岛素甘精胰岛素和口服药物不一致：添加albiglutide，每周GLp-1受体激动剂，与三聚体 - 每日膳食胰岛素Lispro的比较。

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

作者
Rosenstock, Julio; Fonseca, Vivian A; Gross, Jorge L; Ratner, Robert E; Ahrén, Bo; Chow, Francis C C; Yang, Fred; Miller, Diane; Johnson, Susan L; Stewart, Murray W; Leiter, Lawrence A;
展开▼
作者单位

展开▼
年度 2014
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Advancing basal insulin replacement in type 2 diabetes inadequately controlled with insulin glargine plus oral agents: A comparison of adding albiglutide, a weekly GLP-1 receptor agonist, versus thrice-daily prandial insulin lispro [J] . RosenstockJ., FonsecaV.A., GrossJ.L., Diabetes care . 2014,第8期

机译：在甘精胰岛素加口服剂控制不佳的情况下，改善在2型糖尿病中基础胰岛素的替代治疗：每周加用GLP-1受体激动剂阿比鲁肽与每日三次赖脯胰岛素治疗的比较
2. Once-daily basal insulin glargine versus thrice-daily prandial insulin lispro in people with type 2 diabetes on oral hypoglycaemic agents (APOLLO): an open randomised controlled trial. [J] . Bretzel RG, Nuber U, Landgraf W The Lancet . 2008,第9618期

机译：2型糖尿病患者口服降糖药（APOLLO）每日一次基础胰岛素甘精胰岛素vs三次每日餐前赖脯胰岛素：一项开放随机对照试验。
3. Advancing insulin therapy in type 2 diabetes previously treated with glargine plus oral agents: prandial premixed (insulin lispro protamine suspension/lispro) versus basal/bolus (glargine/lispro) therapy. [J] . Rosenstock J, Ahmann AJ, Colon G, Diabetes care . 2008,第1期

机译：推进先前使用甘精胰岛素加口服药物治疗的2型糖尿病的胰岛素治疗：餐前预混合（胰岛素赖脯蛋白鱼精蛋白悬浮液/赖脯胰岛素）与基础/推注（甘精胰岛素/赖脯胰岛素）治疗。
4. TITLE: 6-month administration of Oral Insulin at Lunchtime in Juvenile Type-1 DM Subjects on Basal Glargine Insulin and Pre-Breakfast and Pre-Dinner Regular Insulin [C] . Jaime Guevara-Aguirre, Marco Guevara-Aguirre, Jeannette Saavedra, Controlled Release Society Annual Meeting and Exposition . 2007

机译：标题：午餐时间为1型DM少年受试者接受基础甘草碱胰岛素和早餐前和晚餐前常规胰岛素的口服胰岛素治疗，为期6个月
5. Evaluating Hypoglycemic Risk of Two Basal Insulin Delivery Methods for Type 1 Diabetes: A Comparison of Tresiba Insulin Against Continuous Subcutaneous Insulin Infusion Using Data from Continuous Glucose Monitors [D] . Lane, Benjamin. 2020

机译：评估1型糖尿病两种基础胰岛素递送方法的低血糖风险：使用来自连续葡萄糖监测器的数据进行TRESIBA胰岛素对连续皮下胰岛素输注的比较
6. Impact of a Weekly Glucagon-Like Peptide 1 Receptor Agonist Albiglutide on Glycemic Control and on Reducing Prandial Insulin Use in Type 2 Diabetes Inadequately Controlled on Multiple Insulin Therapy: A Randomized Trial [O] . Julio Rosenstock, Antonio Nino, Joseph Soffer, 2020

机译：每周胰高血糖素样肽1受体激动剂β1-蛋白质血糖控制和减少2型糖尿病患者的糖尿病在多种胰岛素治疗中的糖尿病中的影响：随机试验
7. Once-daily basal insulin glargine versus thrice-daily prandial insulin lispro in people with type 2 diabetes on oral hypoglycaemic agents (APOLLO): an open randomised controlled trial [O] . Bretzel RG, Nuber U, Landgraf W, 2008

机译：2型糖尿病患者口服降糖药（APOLLO）每日一次基础胰岛素甘精胰岛素vs每日三次餐前赖脯胰岛素：一项开放随机对照试验

Advancing Basal Insulin Replacement in Type 2 Diabetes Inadequately Controlled With Insulin Glargine Plus Oral Agents: A Comparison of Adding Albiglutide, a Weekly GLP-1 Receptor Agonist, Versus Thrice-Daily Prandial Insulin Lispro.

著录项

相似文献

相关主题

期刊订阅